Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.51 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049097 | 0.88 | ADORA2B (0.64) | ADORA2BADORA1ADORA2AADORA3MAP4K4 | |
| SCHEMBL4051186 | 0.82 | ADORA2B (0.59) | ADORA2BADORA1ADORA2AADORA3MAP4K4 | |
| SCHEMBL4054625 | 0.81 | ADORA2B (0.56) | ADORA2BADORA1ADORA2AADORA3MAP4K4 | |
| SCHEMBL4052005 | 0.81 | ADORA2B (0.61) | ADORA2BADORA1ADORA2AADORA3MAP4K4 | |
| SCHEMBL4057562 | 0.80 | ADORA2B (0.61) | ADORA2BADORA1ADORA2AADORA3MAP4K4 | |
| SCHEMBL5242786 | 0.79 | ADORA2B (0.65) | ADORA2BADORA1ADORA2AADORA3MAP4K4 | |
| SCHEMBL4053119 | 0.78 | ADORA2B (0.66) | ADORA2BADORA1ADORA2AADORA3MAP4K4 | |
| SCHEMBL4049342 | 0.78 | ADORA2B (0.57) | ADORA2BADORA1ADORA2AADORA3MAP4K4 | |
| SCHEMBL4055140 | 0.78 | ADORA2B (0.58) | ADORA2BADORA1ADORA2AADORA3MAP4K4 | |
| SCHEMBL4055130 | 0.78 | ADORA2B (0.58) | ADORA2BADORA1ADORA2AADORA3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1942469-B | Condensed pyridine derivatives useful as A28 adenosine receptor antagonists | ALMIRALL LAB | 2010-07-07 | — | — | CN | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| CN-1942469-A | Condensed pyridine derivatives useful as A28 adenosine receptor antagonists | ALMIRALL LAB (ES) | 2007-04-04 | — | — | CN | disclosed |
| EP-1735310-A1 | CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005100353-A1 | CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA, SA (ES) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.